OBJECTIVES: Correct diagnosis of inflammatory bowel disease (IBD), especially the
differentiation between Crohn's disease (CD) and ulcerative colitis (UC), is highly important …

BACKGROUND & AIMS: In the absence of pathognomonic markers for Crohn's disease
(CD) and ulcerative colitis (UC), the diagnosis of inflammatory bowel disease depends on a …

BACKGROUND & AIMS:: Infliximab therapy is an effective approach to treating Crohn's
disease. Development of antinuclear antibodies has been described in patients treated, but …

Background and aims: Several antibodies have been associated with Crohn's disease and
are associated with distinct clinical phenotypes. The aim of this study was to determine …

Background Evidence that a deficient innate immune response toward the bacterial flora of
the gut plays a role in the pathogenesis of inflammatory bowel disease (IBD) is growing. This …

Background: Infliximab treatment is effective in 70–80% of patients with refractory luminal
and fistulizing Crohn's disease. The effect of infliximab is ascribed to induction of apoptosis …

Summary Background Serologic markers anti-Saccharomyces cerevisiae antibodies (ASCA)
and antineutrophil cytoplasmic antibodies with perinuclear staining (pANCA) have been …

Background: The role of tumour necrosis factor‐α in the pathogenesis of inflammatory bowel
disorders is well‐known and is underscored by the effectiveness of antitumour necrosis …

Background & Aims: Anti–Saccharomyces cerevisiae antibody (ASCA) is a serologic marker
associated with Crohn's disease (CD). Although there is still discussion on its clinical value …

OBJECTIVES: The use of monoclonal anti-tumor necrosis factor (TNF) antibodies (infliximab,
Remicade) is a new therapeutic approach for severe refractory luminal or fistulizing, Crohn's …